Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Teuber

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Medizinische Klinik (Munich, Germany : 1983)|December 15, 1996
[Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus]G Teuber, A Schwarting, P Mildenberger, et al.
Zeitschrift Fur Gastroenterologie|September 24, 1999
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis CR M Hoffmann, T Berg, G Teuber, et al.
Digestion|July 19, 2000
Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infectionT Konrad, S Zeuzem, G Toffolo, et al.
European Journal of Clinical Investigation|January 29, 2000
Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alphaT Konrad, S Zeuzem, P Vicini, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|October 30, 1999
Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver diseaseT Konrad, P Vicini, S Zeuzem, et al.
Journal of Viral Hepatitis|February 18, 2010
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE studyT Witthoeft, D Hueppe, C John, et al.
Journal of Viral Hepatitis|September 21, 2010
Estimating the likelihood of sustained virological response in chronic hepatitis C therapyS Mauss, D Hueppe, C John, et al.
Journal of Viral Hepatitis|December 17, 2013
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trialJ Wiegand, H Wedemeyer, A Franke, et al.
Journal of Viral Hepatitis|March 26, 2017
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C RegistryT M Welzel, H Hinrichsen, C Sarrazin, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Medizinische Klinik (Munich, Germany : 1983)|December 15, 1996
[Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus]G Teuber, A Schwarting, P Mildenberger, et al.
Zeitschrift Fur Gastroenterologie|September 24, 1999
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis CR M Hoffmann, T Berg, G Teuber, et al.
Digestion|July 19, 2000
Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infectionT Konrad, S Zeuzem, G Toffolo, et al.
European Journal of Clinical Investigation|January 29, 2000
Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alphaT Konrad, S Zeuzem, P Vicini, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|October 30, 1999
Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver diseaseT Konrad, P Vicini, S Zeuzem, et al.
Journal of Viral Hepatitis|February 18, 2010
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE studyT Witthoeft, D Hueppe, C John, et al.
Journal of Viral Hepatitis|September 21, 2010
Estimating the likelihood of sustained virological response in chronic hepatitis C therapyS Mauss, D Hueppe, C John, et al.
Journal of Viral Hepatitis|December 17, 2013
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trialJ Wiegand, H Wedemeyer, A Franke, et al.
Journal of Viral Hepatitis|March 26, 2017
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C RegistryT M Welzel, H Hinrichsen, C Sarrazin, et al.
Pageof 4